Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00004939

Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Clinical Trial

Clinical Trial Summary

OBJECTIVES:

I. Assess the efficacy of 3,4-diaminopyridine in patients with stable chronic demyelinating polyneuropathy.

Clinical Trial Description

PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are randomly assigned to oral 3,4-diaminopyridine (3,4-DAP) or placebo administered for 4 days. After a washout of at least 5 days, patients cross to the alternate therapy for 4 days. ;

Study Design

Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00004939
Study type Interventional
Source Office of Rare Diseases (ORD)
Contact
Status Completed
Phase Phase 3
Start date August 1996
Completion date August 1996
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05327114 - Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Phase 2/Phase 3
Recruiting NCT02271724 - sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN N/A
Completed NCT00004772 - Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Phase 3
Completed NCT03008733 - Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuropathy With Antibody A MAG N/A
Active, not recruiting NCT05877040 - A Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune Therapy Phase 2
Completed NCT02027701 - Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Phase 3
Terminated NCT03275740 - A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 Phase 1
Completed NCT00004286 - Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Phase 3
Completed NCT04742374 - Effects of Single Plasma Exchange and Double Filtration Plasmapheresis (DFPP) on Peripheral Lymphocyte Phenotypes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Early Phase 1
Completed NCT00305266 - Study of CIDP Patients During IVIG Treatment N/A
Completed NCT01017159 - Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Phase 2
Completed NCT00220740 - Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Phase 3
Completed NCT06325943 - Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Phase 3